Owens R E, Fleeger J L, Harms P G
Endocr Res Commun. 1980;7(2):99-105. doi: 10.1080/07435808009065963.
A pharmacologic study using 2-Br-alpha-ergocryptine (CB-154), a dopamine (DA) receptor agonist, the pimozide, a specific DA receptor antagonist, was undertaken to evaluate effects of manipulation of the DA system on plasma LH levels and on the ability of the pituitary to release LH following LHRH stimulation. Intraveneous administration of CB-154 lowered plasma LH levels in ovariectomized rats. Prior treatment with pimozide blocked the effect of CB-154, supporting dopaminergic system mediation in the observed response. Inhibition of LH release by pharmacologic stimulation of DA receptors did not appear to occur at the level of the pituitary, as pituitary release of LH following LHRH was not altered in CB-154 treated rats.
使用多巴胺（DA）受体激动剂2-溴-α-麦角隐亭（CB-154）和特异性DA受体拮抗剂匹莫齐特进行了一项药理学研究，以评估对DA系统的调控对血浆促黄体生成素（LH）水平以及垂体在促性腺激素释放激素（LHRH）刺激后释放LH能力的影响。静脉注射CB-154可降低去卵巢大鼠的血浆LH水平。预先用匹莫齐特治疗可阻断CB-154的作用，这支持了所观察到的反应中多巴胺能系统的介导作用。通过药物刺激DA受体对LH释放的抑制似乎并非发生在垂体水平，因为在接受CB-154治疗的大鼠中，LHRH刺激后垂体释放LH并未改变。
